ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
BASF says it will produce 2’-fucosyllactose, a human milk oligosaccharide (HMO), for the infant nutrition market as part of its Newtrition brand. The company plans to make the HMO, which naturally occurs in human breast milk, via fermentation. It has received approval from the European Union and says it is working toward approval in other countries. Adding HMOs to infant formula can narrow the functional gap with mothers’ milk, BASF says. HMOs, including 2’-fucosyllactose, already appear in some brands of infant formula.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X